<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171493</url>
  </required_header>
  <id_info>
    <org_study_id>VYR-MV1-102</org_study_id>
    <nct_id>NCT03171493</nct_id>
  </id_info>
  <brief_title>Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy</brief_title>
  <official_title>Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyriad, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vyriad, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study designed to test the tolerability and feasibility of intravesical&#xD;
      therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who&#xD;
      are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study VYR-MV1-102 is a Phase 1 study designed to determine the tolerability, feasibility and&#xD;
      preliminary efficacy of attenuated MV-NIS virus after neoadjuvant intravesical administration&#xD;
      prior to RC in patients with UC who are ineligible for current neoadjuvant chemotherapy.&#xD;
&#xD;
      Investigators will use a novel adaptive trial design that varies the time between TURBT,&#xD;
      virus administration and RC.&#xD;
&#xD;
      Currently, intravesical administration of BCG is delayed four to six weeks after TURBT to&#xD;
      reduce the likelihood of systemic BCG absorption and BCG sepsis. Given this clinical safety&#xD;
      precedent, Investigators propose initial patients be treated within one week of RC to&#xD;
      maximize the time between TURBT and MV-NIS administration.&#xD;
&#xD;
      Subsequent patients will be treated earlier before RC (up to 29 days prior), thereby reducing&#xD;
      the interval between TURBT and virus administration to maximize the treatment duration before&#xD;
      RC. An expansion cohort will also be used to test the feasibility, tolerability and efficacy&#xD;
      of two repeat MV-NIS doses prior to RC. MV-NIS has been proven safe at a dose of 1x1011&#xD;
      TCID50 intravenously in patients lacking MV immunity (Russell 2014), which allays concern for&#xD;
      systemic toxicity after intravesical administration even if post-TURBT administration results&#xD;
      in systemic MV-NIS absorption.&#xD;
&#xD;
      Pathologic downstaging and CR (assessed by T0 rate) at surgery are secondary endpoints,&#xD;
      designed to give an early indication of efficacy potential. This will facilitate future&#xD;
      virotherapy strategies targeting replicative tumor destruction and stimulation of systemic&#xD;
      anti-tumor immunity as possible strategies for neoadjuvant and bladder-sparing therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with intravesical MV-NIS treatment related adverse events (NCI CTCAE; Version 4.03)</measure>
    <time_frame>30 days after cystectomy</time_frame>
    <description>Assessment of safety and toxicity of intravesical MV-NIS administration in patients with Urothelial Carcinoma undergoing cystectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic staging at time of cystectomy following intravesical MV-NIS therapy</measure>
    <time_frame>Measured in bladder specimen following cystectomy (up to 29 days following MV-NIS administration)</time_frame>
    <description>Preliminary assessment of antitumor efficacy of intravesical MV-NIS therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pT0 rate at time of cystectomy following intravesical MV-NIS therapy</measure>
    <time_frame>Measured in bladder specimen following cystectomy (up to 29 days following MV-NIS administration)</time_frame>
    <description>Preliminary assessment of antitumor efficacy of intravesical MV-NIS therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intravesical MV-NIS therapy prior to radical cystectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MV-NIS</intervention_name>
    <description>Attenuated measles virus encoding NIS (MV-NIS)</description>
    <arm_group_label>Intravesical MV-NIS therapy prior to radical cystectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Urothelial carcinoma (UC) of the bladder, with histologic confirmation of&#xD;
             primary UC pathology; indication for Radical cystectomy (RC); ineligibility for&#xD;
             platinum-based neoadjuvant chemotherapy&#xD;
&#xD;
          -  ECOG Performance Status (PS) 0 or 1.&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Willingness to comply with all required protocol procedures including providing&#xD;
             biologic specimens and returning to the clinical study site for follow up visits.&#xD;
&#xD;
          -  Performance status sufficient to undergo RC (in the opinion of the enrolling&#xD;
             urologist) including adequate hematological, liver and kidney function&#xD;
&#xD;
          -  Must be willing to implement contraception throughout study and for 30 days following&#xD;
             RC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Variant UC pathology including but not limited to micropapillary, signet&#xD;
             ring,sarcomatoid, and clear cell variants.&#xD;
&#xD;
          -  Patients with any other prior malignancy are not allowed except for the following:&#xD;
             History of or concurrent non-invasive UC involving a portion of urinary tract outside&#xD;
             of the bladder; Adequately treated basal cell or squamous cell skin cancer; In situ&#xD;
             cervical cancer; Adequately treated Stage I or II cancer from which the patient is&#xD;
             currently incomplete remission or other cancer from which the patient has been&#xD;
             disease-free for 2 years.&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or&#xD;
             any other antibody or drug specifically targeting T-cell co-stimulation or immune&#xD;
             checkpoint pathways.&#xD;
&#xD;
          -  Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration.&#xD;
             Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to&#xD;
             registration&#xD;
&#xD;
          -  Other concurrent investigational therapy (utilized for a non-FDA-approved indication&#xD;
             and in the context of a research investigation).&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Nursing women.&#xD;
&#xD;
          -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
             contraception during treatment and 8 weeks following the completion of study drug&#xD;
             treatment.&#xD;
&#xD;
          -  Allergy to measles vaccine or history of severe reaction to prior measles vaccination.&#xD;
&#xD;
          -  History of organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Bexon, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO - Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shruthi Naik, PhD</last_name>
    <phone>507-722-0891</phone>
    <email>snaik@vyriad.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barb H Duckett</last_name>
    <phone>507-289-0944</phone>
    <email>bduckett@vyriad.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanel Diaz</last_name>
      <phone>305-246-8227</phone>
      <email>YDiaz3@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mark L Gonzalgo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Graham, RN</last_name>
      <phone>504-842-2961</phone>
      <email>rgraham@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Bardot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Kroeninger</last_name>
      <phone>507-538-6107</phone>
      <email>kroeninger.tessa@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Leibovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack R Andrews, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paige E Nichols, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>TURBT</keyword>
  <keyword>Radical cystectomy</keyword>
  <keyword>BCG</keyword>
  <keyword>Muscle Invasive Bladder Cancer</keyword>
  <keyword>Intravesical</keyword>
  <keyword>chemotherapy for bladder cancer</keyword>
  <keyword>Oncolytic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

